In addition, some drug therapies based on BRAF inhibition or combined BRAF and MEK inhibition against MM have been successfully applied in the treatment of melanoma (e.g. vemurafenib, trametinib, dabrafenib and vemurafenib with cotellic) (Chapman et al. 2011; Hauschild et al. 2012; Hu-Lieskovan et al. 2014). This evidence concerns the gene MAP2K7 and melanoma.